Hi everyone,
I came across a bunch of really interesting studies this week, and a few of them are worth a closer look. A single inhaled dose of a psychedelic put more than half of patients with hard-to-treat depression into remission within a week, while placebo helped no one. A large U.S. government study took apart the old idea that a daily glass of wine is good for you and found no safe level of alcohol at all. And a once-daily pill helped people lose almost as much weight as the injectable shots, without a needle.
On the podcast, I sat down with Dr Matt Kaeberlein, one of the most respected and most honest voices in the science of aging, for a grounded, hype-free conversation about what we can actually do to live longer and healthier.
Let’s get into it.
This Week’s Podcast Spotlight
Episode 58: The 4 Pillars of Longevity and Healthspan: Eat, Move, Sleep, Connect with Dr Matt Kaeberlein
I wanted to do this episode because the longevity space has become so loud with supplements, biohacks, and miracle claims that it is hard to know what actually holds up. Dr Kaeberlein has spent more than 25 years studying why we age, and what I appreciate most about him is his honesty. He is one of the most informed people in this field, and also one of the most willing to say when the evidence is thin. We talked about why aging itself, not any single disease, may be the most important thing to target, and why the levers that matter most do not cost anything.
The thread running through our whole conversation is hopeful: aging is biology, and biology can be moved. We may not be able to stop it, but the science says we can slow it down, and the biggest tools are already in your hands.
Three things that stood out from this episode:
- Aging itself is the real risk factor. Kaeberlein points out that nine of the ten leading causes of death share the same root driver, biological aging, which means slowing it could push back many diseases at once.
- The four pillars that beat any pill are free. Eating well, moving your body, sleeping enough, and staying socially connected do more for your healthspan than anything sold in a bottle.
- Rapamycin is the most promising longevity drug, with honest caveats. It is the one compound with real evidence for slowing aging in animals, but the right human dose and proof are still unsettled.
If you care about living not just longer but better, this is one of the most useful conversations I have had on the show.
This Week in Health Science
Here is what stood out from the research this week. These studies fascinated me, and I think you will find them practically useful.
One Inhaled Dose of a Psychedelic Put Hard-to-Treat Depression Into Remission
Treatment-resistant depression is one of the most painful problems I see, the kind where one antidepressant after another fails. In this trial, patients inhaled a single dose of a short-acting psychedelic called GH001, and within a week more than half were in remission, while not a single person on placebo got there. The treatment group dropped 15.2 points on a standard depression scale, which is an enormous effect for one dose. The drug is inhaled and acts fast, so the experience is brief and happens under supervision. It is worth keeping expectations measured, because this was an early controlled trial and we need longer follow-up to know how durable the benefit is. But for people who have run out of options, the idea that a single supervised dose could lift them out of a deep depression in days is a real reason for hope.
Key finding: One inhaled dose of the psychedelic GH001 put more than half of patients with treatment-resistant depression into remission within a week, with a 15.2-point drop on a standard depression scale, while placebo helped no one.
A Daily Pill Helped People Lose Nearly 12 Percent of Their Weight, No Needle Required
The biggest barrier I hear about with GLP-1 drugs like Ozempic is the needle, so this one caught my attention. In a phase 2 trial, a once-daily oral GLP-1 pill called elecoglipron helped adults with obesity lose about 11.8 percent of their body weight over 36 weeks, compared with roughly 0.3 percent on placebo. That is approaching the territory of the injectable medications, in a form you simply swallow. A pill is easier to start, easier to stay on, and far less intimidating for people who are needle-averse. This is still an early-stage trial, so we need the larger phase 3 results to confirm both the weight loss and the safety over time. Still, a needle-free option that works this well could open the door for a lot of people who want help but have avoided the shots.
Key finding: A once-daily oral GLP-1 pill called elecoglipron helped adults with obesity lose about 11.8 percent of their body weight in 36 weeks, compared with 0.3 percent on placebo, approaching the results of injectable drugs.
There Is No Safe Level of Alcohol, a Major Government Study Found
The idea that a daily glass of red wine is fine, maybe even good for the heart, has been around for a long time. A large U.S. government analysis, the Alcohol Intake and Health Study, went back and looked hard at the evidence and found no safe level of alcohol and no real health benefit at any amount. Even one drink a day was tied to a higher chance of dying from liver disease, certain cancers, and injuries. The old protective signal for the heart appears to have been a statistical mirage created by comparing drinkers to people who had quit because they were already sick. I am not here to tell anyone how to live, and an occasional drink is a personal choice. But the science no longer supports the idea that alcohol is doing your health any favors.
Key finding: A large U.S. government study found no safe level of alcohol and no real health benefit at any amount, with even one drink a day tied to a higher risk of death from liver disease, cancer, and injury.
It Is the Fryer, Not the Potato: French Fries Raise Diabetes Risk
I love this study because it rescues a food that gets unfairly blamed. In a large analysis of more than 205,000 US adults, eating French fries three times a week was linked to a 20 percent higher risk of type 2 diabetes. But baked, boiled, and mashed potatoes showed no meaningful link to the disease at all. The problem, in other words, is not the potato. It is what happens to it in hot oil.
Here is the part I keep coming back to, and it is my own opinion rather than something this study set out to prove. If glycemic load were the whole story, then baked, boiled, and mashed potatoes, which still raise blood sugar, should have moved the needle too. They did not. To me, the cleanest explanation for why fries stand apart is not the carbohydrate. It is the oil. French fries are almost always cooked in industrial seed oils, the kind I talk about often on the podcast. When these oils are heated to high temperatures and reused for hours, they become highly oxidized, and when we eat them they drive oxidation and inflammation in the body. I increasingly think of metabolic risk less in terms of glycemic load alone and more in terms of these oxidative and inflammatory inputs. A baked potato and a French fry start as the same vegetable. What separates them is what we do to that potato in the fryer. If I had to bet on the real driver of this risk gap, I would bet on the oil, not the starch. When I want fried foods at home, I reach for stable fats like ghee, tallow, or coconut oil rather than seed oils.
If you love potatoes, this is really good news. Bake them, boil them, or mash them, go easy on the deep fryer, and you can keep them on the menu.
Key finding: In more than 205,000 US adults, eating French fries three times a week was linked to a 20 percent higher risk of type 2 diabetes, while baked, boiled, and mashed potatoes showed no meaningful link.
The High-Dose Flu Shot May Lower Alzheimer’s Risk in Older Adults
This one ties in nicely with my longevity conversation this week, because it is another example of a simple, accessible choice that may protect the brain. Researchers already knew that getting any flu shot seems to lower the risk of Alzheimer’s. This large study went further and compared the high-dose flu shot, the version designed for older adults, against the standard-dose one. People who got the high-dose vaccine had a lower risk of Alzheimer’s dementia, with the benefit showing up in the first one to 25 months and the strongest effect in women. Because this is observational, it cannot prove the shot itself is doing the protecting, and healthier people may be more likely to get vaccinated. But the signal lines up with earlier work, and if you are in the age group where the high-dose shot is offered, this is one more reason to ask for it by name.
Key finding: In a large study of older adults, the high-dose flu shot was linked to a lower risk of Alzheimer’s dementia than the standard-dose shot, with the benefit appearing in the first 1 to 25 months and strongest in women.
Stay curious. Stay skeptical. And stay healthy.
Dr Kumar